CA2974781A1 - Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs - Google Patents

Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs Download PDF

Info

Publication number
CA2974781A1
CA2974781A1 CA2974781A CA2974781A CA2974781A1 CA 2974781 A1 CA2974781 A1 CA 2974781A1 CA 2974781 A CA2974781 A CA 2974781A CA 2974781 A CA2974781 A CA 2974781A CA 2974781 A1 CA2974781 A1 CA 2974781A1
Authority
CA
Canada
Prior art keywords
hydroxy
rock2
cells
patient
rho kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2974781A
Other languages
English (en)
Other versions
CA2974781C (fr
Inventor
Kenneth M. Rosen
Matthew D. Abbinanti
Joerg RUSCHEL
Lisa Mckerracher
Lisa Bond Moritz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioaxone Biosciences Inc
Original Assignee
Bioaxone Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioaxone Biosciences Inc filed Critical Bioaxone Biosciences Inc
Priority to CA2974781A priority Critical patent/CA2974781C/fr
Publication of CA2974781A1 publication Critical patent/CA2974781A1/fr
Application granted granted Critical
Publication of CA2974781C publication Critical patent/CA2974781C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2974781A 2017-07-28 2017-07-28 Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs Active CA2974781C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2974781A CA2974781C (fr) 2017-07-28 2017-07-28 Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2974781A CA2974781C (fr) 2017-07-28 2017-07-28 Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs

Publications (2)

Publication Number Publication Date
CA2974781A1 true CA2974781A1 (fr) 2019-01-28
CA2974781C CA2974781C (fr) 2025-09-16

Family

ID=65229093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974781A Active CA2974781C (fr) 2017-07-28 2017-07-28 Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs

Country Status (1)

Country Link
CA (1) CA2974781C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111707832A (zh) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肾损害中的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111707832A (zh) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肾损害中的应用
CN111707832B (zh) * 2020-07-16 2023-08-15 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肾损害中的应用

Also Published As

Publication number Publication date
CA2974781C (fr) 2025-09-16

Similar Documents

Publication Publication Date Title
US10526313B2 (en) Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
EP3558314B1 (fr) Inhibiteur ba-1049 (r) de rho kinase et ses métabolites actifs
US12384759B2 (en) Rho kinase inhibitor ba-1049 (r) and active metabolites thereof
CN113993590B (zh) 新型egfr抑制剂
KR102836833B1 (ko) 신규 메틸퀴나졸리논 유도체
JP6887996B2 (ja) Ｔｅａｄ転写因子自己パルミトイル化阻害剤
JP2021169450A (ja) ヒトｅｚｈ２の阻害剤、およびその使用方法
JP6684831B2 (ja) 化合物
JP6041843B2 (ja) ＩＬ−１ｒａの凝集を低下させる方法
TWI836777B (zh) N-(2-氯-3-((5-氯-3-甲基-4-側氧基-3,4-二氫喹唑啉-6-基)胺基)-4-氟苯基)-3-氟吖呾-1-磺醯胺之結晶形式
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
CA2974781C (fr) Inhibiteur ba-1049 (r) de rho kinase et ses metabolites actifs
CN108676009B (zh) 作为her2酪氨酸激酶抑制剂的嘧啶衍生物及其应用
JP2022500416A (ja) がんを処置するためのキットおよび方法
CN118414152A (zh) 治疗神经系统和心血管病状的方法
CN106632253A (zh) 一种取代的喹啉化合物的晶型及其药物组合物和用途
RU2802968C1 (ru) Новые производные метилхиназолинона
WO2018203559A1 (fr) Compositions pharmaceutiques pour les maladies à expansion de polyglutamine
WO2026062665A1 (fr) Composés à base de sulfonamide et leur utilisation en tant qu'inhibiteurs de fto
HK40113036A (zh) 新颖甲基喹唑啉酮衍生物
CN116162093A (zh) 一种tyk2抑制剂化合物及其用途
HK40093043A (zh) GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
JP2021509398A (ja) 二重作用ｆｋｂｐ１２およびｆｋｂｐ５２阻害剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220420

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20240823

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240910

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250127

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250127

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250207

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-4-4-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250708

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250915

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250916